Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target $43.60 -0.79 (-1.77%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 23 Analyst RatingsSell1Hold3Buy19 Based on 23 Wall Street analysts who have issued ratings for Ionis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 3 have given a hold rating, and 19 have given a buy rating for IONS. Consensus Price Target $89.48105.20% Upside According to the 23 analysts' twelve-month price targets for Ionis Pharmaceuticals, the average price target is $89.48. The highest price target for IONS is $129.00, while the lowest price target for IONS is $56.00. The average price target represents a forecasted upside of 105.20% from the current price of $43.61. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for IONS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Analyst Ratings Over TimeTypeCurrent Forecast10/30/25 to 10/30/261 Month Ago9/30/25 to 9/30/263 Months Ago8/1/25 to 8/1/261 Year Ago10/30/24 to 10/30/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy19 Buy rating(s)17 Buy rating(s)18 Buy rating(s)16 Buy rating(s)Hold3 Hold rating(s)4 Hold rating(s)3 Hold rating(s)3 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$89.48$89.20$94.85$81.05Forecasted Upside105.20% Upside99.78% Upside83.21% Upside9.28% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy IONS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History IONS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Ionis Pharmaceuticals Stock vs. The CompetitionTypeIonis PharmaceuticalsHealthcare CompaniesBroader MarketConsensus Rating Score 2.78 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside101.57% Upside107.58% Upside15.04% UpsideNews Sentiment RatingNeutral NewsSee Recent IONS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/30/2024 - 10/30/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/22/2026 HC Wainwright4 of 5 starsMitchell S. Kapoor3 of 5 starsReiterated RatingBuy10/22/2026 BMO Capital Markets3 of 5 starsDavid LebowitzNot RatedUpgradeMarket Perform ➝ Outperform$54.00 ➝ $66.00+49.09%10/21/2026 Citigroup4 of 5 starsEric JosephNot RatedReiterated RatingBuy10/20/2026 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsTiago FauthSubscribe to MarketBeat All Access to unlock analyst rankingsSet Target$79.00+75.97%10/15/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingSell (D-)10/15/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsJoon LeeSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageNeutral ➝ Buy$46.00 ➝ $88.00+106.09%9/24/2026 OppenheimerSubscribe to MarketBeat All Access to unlock brokerage rankingsJay OlsonSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOutperform$85.00+93.49%9/22/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsJessica FyeSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$76.00 ➝ $70.00+55.90%9/15/2026 GuggenheimSubscribe to MarketBeat All Access to unlock brokerage rankingsBrad CaninoSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$89.00 ➝ $80.00+55.52%9/9/2026 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsEliana MerleSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$90.00 ➝ $85.00+49.89%Don't lose access to this (Ad)Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.Download your free copy before access ends for good9/8/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsMichael UlzSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$110.00 ➝ $104.00+81.91%9/8/2026 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankingsYaron WerberSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy9/8/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsSalveen RichterSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetNeutral$69.00 ➝ $56.00-3.60%9/8/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsGary NachmanSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$95.00 ➝ $85.00+46.32%9/4/2026 Needham & Company LLCSubscribe to MarketBeat All Access to unlock brokerage rankingsJoseph StringerSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$86.00+47.17%7/30/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsYanan ZhuSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$100.00 ➝ $95.00+78.40%7/16/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsAndy ChenSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeOutperform ➝ Peer Perform7/13/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsLuca IssiSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOutperform$100.00 ➝ $85.00+49.57%7/9/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsAkash TewariSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$113.00 ➝ $90.00+39.52%6/25/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsMani ForooharSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$122.00 ➝ $129.00+64.81%4/9/2026 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankingsJason GerberrySubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$100.00 ➝ $111.00+45.83%2/27/2026 Piper SandlerSubscribe to MarketBeat All Access to unlock brokerage rankingsAllison BratzelSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$87.00 ➝ $100.00+23.05%2/26/2026 Stifel NicolausSubscribe to MarketBeat All Access to unlock brokerage rankingsPaul MatteisSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetHold$73.00 ➝ $77.00-5.60%3/31/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access to unlock brokerage rankingsJoshua SmithSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageNeutral$39.00+25.20%12/20/2024 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOutperformAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:57 AM ET. IONS Forecast - Frequently Asked Questions What is Ionis Pharmaceuticals' forecast for 2026? According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Ionis Pharmaceuticals is $89.48, with a high forecast of $129.00 and a low forecast of $56.00. Should I buy or sell Ionis Pharmaceuticals stock right now? 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IONS shares. Does Ionis Pharmaceuticals's stock price have much upside? According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 105.20% based on their 12-month stock forecasts. Has Ionis Pharmaceuticals been upgraded by Wall Street analysts recently? Over the previous 90 days, Ionis Pharmaceuticals's stock had 2 upgrades by analysts. What analysts cover Ionis Pharmaceuticals? Ionis Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James Financial, TD Cowen, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Ionis Pharmaceuticals more than its competitors? Analysts like Ionis Pharmaceuticals more than other "healthcare" companies. The consensus rating for Ionis Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IONS compares to other companies. Stock Forecasts and Research Tools Related Companies Genmab A/S Stock Forecast Roivant Sciences Stock Forecast United Therapeutics Stock Forecast Incyte Stock Forecast BioNTech Stock Forecast Insmed Stock Forecast Exelixis Stock Forecast Ascendis Pharma A/S Stock Forecast Halozyme Therapeutics Stock Forecast BridgeBio Pharma Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Ionis Pharmaceuticals RecommendationsHC WainwrightBMO Capital MarketsCitigroupRaymond James FinancialWeiss RatingsUBS GroupOppenheimerJPMorgan Chase & Co.GuggenheimBarclaysTD CowenMorgan StanleyCanaccord Genuity GroupThe Goldman Sachs GroupNeedham & Company LLC MarketBeat monitors more than a dozen sources for Ionis Pharmaceuticals analyst ratings, with the most recent rating issued on 10/22/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
